Company intelligence / Profile preview
Skymab Biotherapeutics
Tours, Centre-Val de Loire, Franceskymab-biotherapeutics.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Preclinical
01
Overview
Skymab Biotherapeutics has developed an innovative antibody-drug conjugate platform focused on targeting GPCRs, which are underexploited in the ADC field. The company leverages proprietary bioinformatics to select relevant cancer-associated GPCR targets and aims to deliver first-in-class and best-in-class therapeutics for patients with high unmet needs. As of early/mid 2025, their programs are at late preclinical stage; no clinical results have been published yet.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Protein engineering/biologics
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Participation as a partner at World ADC London events alongside major CDMO/CMO partners such as Ajinomoto Bio-pharma Services, BSP Pharmaceuticals, Merck Millipore CTDMO Services, Synaffix/Lonza.
Beyond the preview
Go deeper on Skymab Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skymab Biotherapeutics.